NYU Langone Celebrates 1,000th Focal Cryotherapy as Veteran Performer Returns to Stage
A Milestone in Minimally Invasive Oncology
NYU Langone Health performed its 1,000th focal cryotherapy on June 5, 2026, marking a milestone in minimally invasive prostate cancer care. Eighty‑year‑old Broadway star André De Shields completed the procedure two days earlier and was already rehearsing for „Cats: The Jellicle Ball,” which opened in April.
The landmark case highlights a broader shift toward survivorship‑focused oncology, where treatments aim to preserve quality of life while eliminating disease. Focal cryotherapy freezes only the cancerous portion of the prostate, sparing surrounding tissue and reducing side effects. NYU’s dedicated Cryotherapy Center reported a steady rise in referrals, driven by patient demand for less invasive options. Dr. Maria Alvarez, director of the program, said the technique „offers rapid recovery and maintains urinary and sexual function for many patients.”
Reaching 1,000 procedures places NYU Langone among the nation’s leading cryotherapy providers. The center attributes its growth to a multidisciplinary approach, integrating urologists, radiologists, and physical therapists. Recent data show a 30 % drop in hospital stays for patients undergoing focal cryotherapy compared with traditional surgery. „Our goal is to treat the tumor without compromising the patient’s daily life,” Dr. Alvarez explained. André De Shields praised the experience, noting he felt „back on my feet” within 48 hours and could sing without discomfort. His swift return to the stage underscores the procedure’s potential to keep patients active during recovery.
Can Cryotherapy Transform Prostate Cancer Treatment?
Experts argue that focal cryotherapy could become a standard option for early‑stage prostate cancer. The method targets only malignant cells, limiting collateral damage and shortening rehabilitation. Ongoing trials at NYU compare long‑term outcomes with radiation therapy, aiming to prove comparable cancer control rates. If results hold, insurers may expand coverage, making the technique more accessible. Critics caution that patient selection is crucial; not all tumors are suitable for focal freezing. Nonetheless, the growing body of evidence suggests a promising future for this less invasive approach.
The 1,000th case signals confidence in cryotherapy’s role within modern oncology. As more patients like André De Shields share positive stories, the procedure may reshape expectations for prostate cancer recovery. NYU plans to increase capacity and train additional surgeons, reinforcing its position at the forefront of survivorship‑oriented care.
Frequently Asked Questions
What is focal cryotherapy? Focal cryotherapy is a minimally invasive treatment that freezes the cancerous part of the prostate while leaving healthy tissue untouched, reducing side effects and speeding recovery.
Who is eligible for this procedure? Typically, men with localized, low‑ to intermediate‑risk prostate tumors qualify. A thorough imaging and biopsy assessment determines suitability.
How does recovery compare to traditional surgery? Patients often resume normal activities within a few days, with shorter hospital stays and fewer urinary or sexual complications than with radical prostatectomy.